Figure S1 from Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma

Hollander, Jan F.; Szymansky, Annabell; Wünschel, Jasmin; Astrahantseff, Kathy; Rosswog, Carolina; Thorwarth, Anne; Thole-Kliesch, Theresa M.; Chamorro González, Rocío; Hundsdörfer, Patrick; Hauptmann, Kathrin; Schmelz, Karin; Gürgen, Dennis; Rogasch, Julian M.M.; Henssen, Anton G.; Fischer, Matthias; Schulte, Johannes H.; Eckert, Cornelia; Eggert, Angelika; Lodrini, Marco; Deubzer, Hedwig E.

doi:10.1158/2767-9764.28295427

Figure S1 from Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma

journal contribution

posted on 2025-01-28, 10:40 authored by Jan F. Hollander, Annabell Szymansky, Jasmin Wünschel, Kathy Astrahantseff, Carolina Rosswog, Anne Thorwarth, Theresa M. Thole-Kliesch, Rocío Chamorro González, Patrick Hundsdörfer, Kathrin Hauptmann, Karin Schmelz, Dennis Gürgen, Julian M.M. Rogasch, Anton G. Henssen, Matthias Fischer, Johannes H. Schulte, Cornelia Eckert, Angelika Eggert, Marco Lodrini, Hedwig E. Deubzer

Figure S1

History

ARTICLE ABSTRACT

Real-time molecular monitoring of TERT-rearranged high-risk neuroblastoma is an unmet clinical need. We tested liquid biopsy-based assays for patient-individualized TERT breakpoint sequences to monitor disease in pediatric patients. Our digital PCR approach provides high resolution of spatial and temporal disease quantification in individual patients and is applicable for clinical routine.

Usage metrics

Keywords

Biomarkers Diagnostic Biomarkers Early Detection Biomarkers Liquid Biopsy Oncogenes Oncogenes & Tumor Suppressors Pediatric Cancers

Licence

CC BY

Figure S1 from Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports